entertainment -WSS

entertainment

author：comprehensive 2025-10-02 11:09:18 - browse：75

Immunofluorescence image shows CD4+ (green) and CD8+ (yellow) T cells in the microenvironment of a head and neck squamous cell carcinoma. — This immunofluorescence image shows T cells (in green and yellow) in the microenvironment of a head and neck squamous cell carcinoma. Allen Lab/NCI/NIH

Merus said Tuesday that the combination of its experimental drug petosemtamab with the checkpoint inhibitor Keytruda shrank tumors in 62% of patients with head and neck cancer, according to an interim analysis of an ongoing mid-stage clinical trial.

The new efficacy results, derived from a larger number of patients, look similar to an initial disclosure made last week that triggered a 36% increase in Merus’ stock price.

But the Dutch drugmaker on Tuesday withheld additional information from the study related to the safety and durability of petosemtamab’s tumor responses, pending presentation at the annual meeting of the American Society of Clinical Oncology on June 3.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Being 'nonadherent' patient made me a more empathetic doctor

hotspot

WSS

Clinical trials must include more disabled people

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

Evacuations in place as 3 wildfires burn in eastern Washington state

Clinical trials must include more disabled people

Penis shrinkage, a side effect of prostate cancer surgery, is temporary

STAT wants to know your pick for a great summer read or listen

explore

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Wildfire smoke exposes gaps in outdoor worker protections

Dexcom's push to bring CGM to type 2 diabetes patients

Peter Hotez and the public health issue of online harassment

Hilary expected to bring catastrophic, life

Tori Bowie and the unacceptable rates of Black maternal death

Living with Hashimoto's and celiac disease, and med school, too

Apple is now the first public company to be valued at $3 trillion

Trump cancels press conference intended to dispute Georgia election interference charges

As demand for Covid shots wanes, Moderna seeks its next success

Beware reading your test results before your doctor does

focus

ActiGraph execs on goal of drug approvals with digital endpoints

Lung cancer is America's deadliest cancer. Yet so few get screened

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

Hilary may become 1st tropical storm to make landfall in California in 84 years

Crowdfunding for unproven stem cell procedures spreads misinformation

Trump cancels press conference intended to dispute Georgia election interference charges

leisure time

knowledge

hotspot

hotspot